TP53 codon 72 polymorphism in patients with chronic myeloid leukemia

Haematologica

Volumn 89, Issue 7, 2004, Pages 868-869

  Bergamaschi, Gaetano ^a,b   Merante, Serena ^a   Orlandi, Ester ^a   Galli, Anna ^a   Bernasconi, Paolo ^a   Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Chronic myeloid leukemia; Imatinib mesylate; Polymorphism; TP53

Indexed keywords

IMATINIB;

ADULT; ALLELE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MALE; POLYMERASE CHAIN REACTION; RNA ISOLATION; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ALLELES; CODON; FEMALE; GENES, P53; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC;

EID: 3242803705     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
2. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
3. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-5.
4. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
5. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994;44:266-70.
6. + cells. Blood 2004 (in press).
7. Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003;88:260-7.
8. O'Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004;103:451-5.
9. Rosti G, Trabacchi E, Bassi S, Bonifazi F, de Vivo A, Martinelli G, et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 2003;88:256-9.
10. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-5.